End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.

Publication

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.

Journal Paper/Review - Jan 31, 2023

Di Cosimo Serena, Ciniselli Chiara M, Pizzamiglio Sara, Cappelletti Vera, Silvestri Marco, El-Abed Sarra, Izquierdo Miguel, Bajji Mohammed, Nuciforo Paolo, Huober Jens, Cameron David, Chia Stephen, Gomez Henry L, Iorio Marilena V, Vingiani Andrea, Pruneri Giancarlo, Verderio Paolo

Citation

Di Cosimo S, Ciniselli C, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez H, Iorio M, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Front Oncol 2023; 12:1028825.

Type

Journal Paper/Review (English)

Journal

Front Oncol 2023; 12

Publication Date

Jan 31, 2023

Issn Print

2234-943X

Pages

1028825

Brief description/objective

The absence of breast cancer cells in surgical specimens, , pathological complete response (pCR), is widely recognized as a favorable prognostic factor after neoadjuvant therapy. In contrast, the presence of disease at surgery characterizes a prognostically heterogeneous group of patients. Here, we challenged circulating microRNAs (miRNAs) at the end of neoadjuvant therapy as potential prognostic biomarkers in the NeoALTTO study.